Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn’s Disease: Results From a Randomised Phase II Biopsy Sub-study-Reference-Cited by-同舟云学术

Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn’s Disease: Results From a Randomised Phase II Biopsy Sub-study

Published:2018-07-19 Issue:10 Volume:12 Page:1170-1179
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:

Author:

Visvanathan Sudha¹,Baum Patrick²,Salas Azucena³,Vinisko Richard¹,Schmid Ramona²,Grebe Kristie M⁴,Davis Justin W⁵,Wallace Kori⁵,Böcher Wulf O⁶,Padula Steven J⁶,Fine Jay S¹,Panés Julián³

Affiliation:

1. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA

2. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

3. Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

4. AbbVie Inc., Worcester, MA, USA

5. AbbVie Inc., North Chicago, IL, USA

6. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Funder

Boehringer Ingelheim

Publisher

Oxford University Press (OUP)

Subject